Clinical Trial for Novel Liver Cancer Drug Begins
According to Jennerex, JX-594 is one of a series of first-in-class, targeted oncolytic poxvirus-based immunotherapies designed to selectively target and destroy cancer cells through 3 diverse mechanisms of action: lysis of cancer cells, destruction of tumor blood supply, and stimulation of the body's immune response against cancer cells.
Previous clinical trials in several cancer types have demonstrated that JX-594, when delivered either directly into tumors or intravenously, is capable of inducing tumor shrinkage and/or cell death and is well-tolerated by patients.
In this trial, the investigators aim to determine “the radiographic response rate based on modified RECIST and modified Choi criteria, followed by subsequent determination of progression-free survival (PFS) and overall survival (OS).”
The trial is being conducted at sites in South Korea, the United States, and Europe.